Gapping down
In reaction to earnings/guidance:
- VRM -11.7%, RVLV -10%, HYLN -7.6%, SPTN -6%, ENR -5.2%, GOCO -5%, SBH -4%, OM -3.6%, FLR -3.1%, TDG -2.6%, GDRX -2.3%, RVMD -1.8%, ATO -1.7% (also increases dividend), SWTX -1.7%, ENS -1.3%, WIX -1.3%, SSYS -1.2%
Other news:
- USCR -6.6% (acquires assets of Sugar City Building Materials)
- ALGT -3.1% (reports October traffic)
- MOR -1.8% (INCY, XNCR and MOR announce global collaboration for tafasitamab)
- PRVL -1.6% (details arbitrator prior decision with FAQ)
- AZN -1.2% (reports CALAVI Phase II trials for Calquence in patients hospitalised with respiratory symptoms of COVID-19 did not meet primary endpoint)
- MPC -1% (new CFO)
- FRC -1% (stock offering)
Analyst comments:
- TBK -2.5% (downgraded to Mkt Perform from Outperform at Keefe Bruyette)
- CRM -1.8% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- IFS -1.5% (downgraded to Neutral from Overweight at JP Morgan)
- ALC -1.4% (downgraded to Neutral from Buy at Guggenheim)
- CFR -1.4% (downgraded to Mkt Perform from Outperform at Keefe Bruyette)
- WSM -1.3% (downgraded to Accumulate from Buy at Gordon Haskett)
- FSK -1% (downgraded to Underweight from Equal Weight at Wells Fargo)